{
    "clinical_study": {
        "@rank": "63675", 
        "arm_group": {
            "arm_group_label": "Dexamethasone Intravitreal Implant", 
            "arm_group_type": "Active Comparator"
        }, 
        "brief_summary": {
            "textblock": "to evaluate the wall-to-lumen ratio (WLR) of retinal arterioles in hypertensive patients\n      with retinal vein occlusion (RVO) before and after dexamethasone intravitreal implant 0.7 mg\n      (DEX) compared to a matched control group of normal eyes in non-hypertensive subjects."
        }, 
        "brief_title": "Diameters and Wall-to-lumen Ratio of Retinal Arterioles in Patients With Retinal Vein Occlusion.", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hypertensive Patients With Retinal Vein Occlusion", 
        "condition_browse": {
            "mesh_term": "Retinal Vein Occlusion"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  ability to provide written informed consent and comply with study assessments for the\n             full duration of the study;\n\n          -  age > 20 years;\n\n          -  decreased visual acuity as a result of clinically detectable ME associated with\n             either CRVO or BRVO;\n\n          -  the duration of macular edema was required to be between 4 and 24 weeks for both CRVO\n             and BRVO;\n\n          -  retinal thickness in the central subfield (as measured using optical coherence\n             tomography) had to be > 350 \u00b5m in the study eye.\n\n        Exclusion Criteria:\n\n          -  the exclusion criteria were as follows: diabetes; previous intravitreal anti-VEGF\n             therapy or intravitreal steroid therapy; previous photodynamic therapy or focal\n             laser; active retinal or optic disc neovascularization; active or history of\n             choroidal neovascularization; presence of rubeosis iridis; any active infection;\n             glaucoma, current ocular hypertension, or a history of steroid-induced intraocular\n             pressure (IOP) increase in either eye; or concurrent eye disease in the study eye\n             that could compromise visual acuity (e.g., choroidal neovascularization, diabetic\n             retinopathy, epiretinal membrane)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01789437", 
            "org_study_id": "DIAMETER-001"
        }, 
        "intervention": {
            "arm_group_label": "Dexamethasone Intravitreal Implant", 
            "intervention_name": "Dexamethasone Intravitreal Implant (Ozuredex)", 
            "intervention_type": "Device"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "retinal vein occlusion", 
            "systemic hypertension", 
            "arteriolar diameter"
        ], 
        "lastchanged_date": "February 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Brescia", 
                    "country": "Italy", 
                    "state": "BS", 
                    "zip": "25124"
                }, 
                "name": "Spedali Civili di Brescia"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "Diameters and Wall-to-lumen Ratio of Retinal Arterioles in Patients With Retinal Vein Occlusion.", 
        "overall_official": {
            "affiliation": "University of Brescia, Italy", 
            "last_name": "Andrea Russo, Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "change of outer arteriolar diameter", 
                "safety_issue": "No", 
                "time_frame": "the primary endpoint was at 6 months"
            }, 
            {
                "measure": "change of inner arteriolar diameter", 
                "safety_issue": "No", 
                "time_frame": "the primary endpoint was at 6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01789437"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universit\u00e0 degli Studi di Brescia", 
            "investigator_full_name": "Andrea Russo", 
            "investigator_title": "Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Secondary outcome measures were as follows: adverse ocular events; mean change in visual acuity; and mean change in central macular thickness.", 
            "safety_issue": "Yes", 
            "time_frame": "Outcomes were analyzed at 4 intermediate time points: 30, 60, 90, and 150 days."
        }, 
        "source": "Universit\u00e0 degli Studi di Brescia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universit\u00e0 degli Studi di Brescia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}